scholarly journals Case report of novel CACNA1A gene mutation causing episodic ataxia type 2

2017 ◽  
Vol 5 ◽  
pp. 2050313X1770604 ◽  
Author(s):  
David Alan Isaacs ◽  
Michael J Bradshaw ◽  
Kelly Brown ◽  
Peter Hedera

Background: Episodic ataxia type 2 (OMIM 108500) is an autosomal dominant channelopathy characterized by paroxysms of ataxia, vertigo, nausea, and other neurologic symptoms. More than 50 mutations of the CACNA1A gene have been discovered in families with episodic ataxia type 2, although 30%–50% of all patients with typical episodic ataxia type 2 phenotype have no detectable mutation of the CACNA1A gene. Case: A 46-year-old Caucasian man, with a long history of bouts of imbalance, vertigo, and nausea, presented to our hospital with 2 weeks of ataxia and headache. Subsequent evaluation revealed a novel mutation in the CACNA1A gene: c.1364 G > A Arg455Gln. Acetazolamide was initiated with symptomatic improvement. Conclusion: This case report expands the list of known CACNA1A mutations associated with episodic ataxia type 2.

2017 ◽  
Vol 376 ◽  
pp. 119-120 ◽  
Author(s):  
Štefan Sivák ◽  
Egon Kurča ◽  
Adriána Krajčiová ◽  
Martina Hikkelová ◽  
Juraj Šimko ◽  
...  

2018 ◽  
Vol 2018 ◽  
pp. 1-3
Author(s):  
Sean Lance ◽  
Stuart Mossman ◽  
Gemma Poke

Episodic ataxia is a heterogenous group of uncommon neurological disorders characterised by recurrent episodes of vertigo, dysarthria, and ataxia for which a variety of different genetic variations have been implicated. Episodic ataxia type two (EA2) is the most common and also has the largest number of identified causative genetic variants. Treatment with acetazolamide is effective in improving symptoms, so accurate diagnosis is essential. However, a large proportion of patients with EA2 have negative genetic testing. We present a patient with a typical history of EA2 who had a novel variant in the CACNA1A gene not previously described. Report of such variations is important in learning more about the disease and improving diagnostic yield for the patient.


2017 ◽  
Vol 161 (1) ◽  
pp. 107-110 ◽  
Author(s):  
Andrea Petrovicova ◽  
Miroslav Brozman ◽  
Egon Kurca ◽  
Tibor Gobo ◽  
Jana Dluha ◽  
...  

2005 ◽  
Vol 62 (2) ◽  
pp. 314 ◽  
Author(s):  
Sian D. Spacey ◽  
Luke A. Materek ◽  
Blajez I. Szczygielski ◽  
Thomas D. Bird

2009 ◽  
Vol 280 (1-2) ◽  
pp. 10-14 ◽  
Author(s):  
Ester Cuenca-León ◽  
Isabel Banchs ◽  
Selma A. Serra ◽  
Pilar Latorre ◽  
Noèlia Fernàndez-Castillo ◽  
...  

Author(s):  
Hiroyuki Hirose ◽  
Takashi Arayama ◽  
Junko Takita ◽  
Takashi Igarashi ◽  
Yasuhide Hayashi ◽  
...  

Cephalalgia ◽  
2009 ◽  
Vol 30 (6) ◽  
pp. 740-743 ◽  
Author(s):  
C Cleves ◽  
S Parikh ◽  
AD Rothner ◽  
SJ Tepper

An association between hemiplegic migraine (HM) and episodic ataxia type 2 (EA2) has been described; both disorders are linked to mutations in the CACNA1A gene. Although confusion occurs in 21% of patients with HM, we found only one case in the literature of confusional episodes associated with ataxia without hemiplegia. These findings raise the possibility of confusional episodes being part of both the HM and EA2 phenotype. However, a patient with episodic ataxia, confusional spells and CACNA1A gene mutations has not been identified. We describe four individuals, spanning three generations of a family, with episodic ataxia without hemiplegia and confusion, in association with a CACNA1A mutation. We follow with a description of the relationship between the CACNA1A mutations and the three syndromes, suggesting a potential need for a new classification in which the conditions can be subsumed.


2021 ◽  
pp. 100334
Author(s):  
Lorenzo Verriello ◽  
Paola Carrera ◽  
Giada Pauletto ◽  
Andrea Bernardini ◽  
Mariarosaria Valente ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document